Dimensional Fund Advisors’s Sagimet Biosciences SGMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.21M Buy
527,478
+129,506
+33% +$1.19M ﹤0.01% 2490
2026
Q2
$3.08M Buy
397,972
+126,755
+47% +$862K ﹤0.01% 2637
2026
Q1
$1.41M Buy
271,217
+135,178
+99% +$753K ﹤0.01% 2774
2025
Q4
$805K Buy
136,039
+110,705
+437% +$795K ﹤0.01% 2893
2025
Q3
$174K Hold
25,334
– – ﹤0.01% 3135
2025
Q2
$193K Hold
25,334
– – ﹤0.01% 3120
2025
Q1
$82.7K Hold
25,334
– – ﹤0.01% 3221
2024
Q4
$114K Buy
+25,334
New +$128K ﹤0.01% 3229

Other funds holding SGMT

Dimensional Fund Advisors's SGMT Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Sagimet Biosciences (SGMT) stake by 33% in Q3 2026, buying an estimated $1.19M and bringing the position to 527,478 shares worth $5.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2490.

Dimensional Fund Advisors first reported a position in SGMT in Q4 2024 and has held it in 8 quarters since. 153 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

  • Dimensional Fund Advisors held 527,478 shares of Sagimet Biosciences worth $5.21M as of Q3 2026.
  • Dimensional Fund Advisors bought 129,506 Sagimet Biosciences shares in Q3 2026, an estimated $1.19M.
  • Sagimet Biosciences made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2490 holding.
  • Dimensional Fund Advisors first reported a position in Sagimet Biosciences in Q4 2024 and has held it in 8 quarters since.
  • 153 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.